Anecdotal evidence suggests that some EGFR mutation-positive patients benefit from PD-1/PD-L1 inhibitors.[9]EGFR exon 20 mutations demonstrated a higher response rate and longer survival compared to classic EGFR mutations.[10] A case report demonstrated that a heavily pre-treated patient of NSCLC with EGFR exon 20 insertion mutation responded to ICIs-based therapy.[11] But the effect of upfront ICIs in lung cancer patients harboring EGFR exon 20 insertion mutation is lacking. Here, PDCD1 is linked to lung carcinoma.